Crsp analyst ratings
Web2 days ago · View real-time CRSP stock price and news, along with industry-best analysis. ... Analyst Ratings. Average price target from 29 ratings: $78.76. ... Fundamental … Web2 days ago · The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 105.3% upside in the stock. While this highly sought-after metric has not …
Crsp analyst ratings
Did you know?
Web20 hours ago · Cathie Wood Buys CRSP Stock Before Cantor Price Target Initiation Cantor analyst Olivia Brayer has initiated coverage of Crispr with an “overweight” rating and a … WebMar 21, 2024 · According to 11 analyst offering 12-month price targets in the last 3 months, CRISPR Therapeutics has an average price target of $71.91 with a high of $123.00 and …
Web23 hours ago · The analyst sees a lot of momentum to come back into this stock, starting with the ongoing exa-cel regulatory review. Price Action: CRSP shares are up 15.50% at $50.22 on the last check Thursday. WebApr 13, 2024 · Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $72.84. CRISPR Therapeutics Profile ( Get Rating)
WebApr 13, 2024 · Get Wall Street analysts ratings for CRISPR Therapeutics AG (CRSP). Buy or Sell this stock? See what the analysts say. Web23 hours ago · Shares of CRISPR Therapeutics (CRSP 16.31%) were up 15% Thursday morning, a day after a drug-pricing group said the company's single-dose therapy for …
Web23 hours ago · CRSP +14.8% + Free Alerts with an Overweight rating and a price target of $72, citing an interesting gene editing play for 2024. The company has an excellent …
Web2 days ago · The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 105.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ... jaybird bluebuds x refurbishedWebMay 17, 2024 · Analyst Ratings for CRISPR Therapeutics. Benzinga. May. 17, 2024, 12:03 PM. Over the past 3 months, 11 analysts have published their opinion on CRISPR … jaybird bluebuds x bluetooth 4.0Web23 hours ago · Shares of CRISPR Therapeutics ( CRSP 16.66%) were up 15% Thursday morning, a day after a drug-pricing group said the company's single-dose therapy for sickle cell disease (SCD) could be cost... jaybird bluebuds x bluetooth earbudWeb1 day ago · Upgrades. UBS upgraded the previous rating for Ingredion Inc INGR from Neutral to Buy. For the fourth quarter, Ingredion had an EPS of $1.65, compared to year-ago quarter EPS of $1.09. jaybird bluebuds x review amazonWebCRSP will report Q1 2024 earnings on 05/09/2024 EPS Surprise Estimate Actual Q1 2024 Q2 2024 Q3 2024 Q4 2024 -3 -2 -1 Analyst Ratings Upgrades/Downgrades View All Upgrades & Downgrades FY... jaybird bluebuds x replacement ear cushionsWebCRSP Analyst Ratings Moderate Buy 17 Ratings 9 Buy 7 Hold 1 Sell Based on 17 analysts giving stock ratings to Crispr Therapeutics AG in the past 3 months CRSP … jaybird bluebuds x sport headphonesWebMar 21, 2024 · Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $74.59. CRISPR Therapeutics Price Performance low salinity meaning